PATHOLOGY RESEARCH AND PRACTICE is a premier journal in the field of pathology and forensic medicine, published by Elsevier GmbH in Germany. With a rich publication history since 1978 and an impressive convergence period extending to 2024, this journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of pathological processes. It holds notable rankings, including Q3 in Cell Biology and Q2 in Pathology and Forensic Medicine for 2023, reflecting its significance in the academic community. The journal aims to publish innovative research findings, reviews, and case studies, facilitating a deeper understanding of disease mechanisms and improving diagnostic practices. Authors and readers alike benefit from its reputable platform, noted for its challenging and rigorous peer-review process. By fostering a collaborative environment and providing open access options, PATHOLOGY RESEARCH AND PRACTICE continues to contribute meaningfully to the discourse within its respective fields, thereby appealing to a diverse audience of researchers, professionals, and students.

Malaysian Journal of Pathology, published by the MALAYSIAN JOURNAL PATHOLOGY, stands as a pivotal resource in the fields of pathology and medicine, contributing rich insights since its inception in 1979. This peer-reviewed journal, based in Malaysia, is dedicated to disseminating original research, review articles, and case studies that advance the understanding of disease mechanisms and diagnostics. With a current impact factor reflecting its ranked positioning—Q4 in Cell Biology, Q4 in Histology, and Q3 in both Miscellaneous Medicine and Pathology & Forensic Medicine—this journal serves as an essential platform for researchers, clinicians, and students alike. Although it operates without open access, its scholarly rigor and contributions are well recognized, holding ranks such as #84 in Pathology and Forensic Medicine according to Scopus. The Malaysian Journal of Pathology is committed to fostering innovation and excellence in medical research, making it an invaluable tool for professionals seeking to stay abreast of significant advancements in the pathology domain.

Genes and Environment is a premier interdisciplinary journal published by BMC that explores the dynamic interplay between genetic factors and environmental influences shaping health and behavior. Since its inception, the journal has gained recognition for its commitment to providing open access (since 2015) to groundbreaking research, fostering an inclusive platform for scholars worldwide. With an ISSN of 1880-7046 and an E-ISSN of 1880-7062, Genes and Environment consistently ranks in Q2 in Environmental Science, Q3 in Genetics, and Q2 in Social Psychology according to the 2023 category quartiles, highlighting its significant contributions to these fields. The journal is headquartered in the United Kingdom and has a diverse portfolio of research spanning from 2006 to 2024. It is recognized in Scopus with commendable rankings across various disciplines. By fostering dialogue among researchers, professionals, and students, Genes and Environment serves as a vital resource for understanding complex biological interactions with environmental factors, ultimately aiming to advance knowledge and inform public policy.

Clinical Epigenetics is a pioneering open-access journal published by BMC, dedicated to advancing the field of epigenetics and its critical implications in clinical and translational research. Established in 2011, the journal has become an authoritative resource in the realms of developmental biology, genetics, and molecular biology, as evidenced by its impressive 2023 Scopus categorization as a Q1 journal in multiple domains including clinical genetics. With a robust impact factor and rankings that place it among the top quartiles in its fields—Rank #13 in Clinical Genetics and #14 in Developmental Biology—Clinical Epigenetics serves as an essential platform for researchers, professionals, and students alike, encouraging the dissemination of high-quality research findings. Operating from its United Kingdom headquarters, this journal not only contributes to scholarly dialogue across the globe but also supports unrestricted access to vital findings that push the boundaries of our understanding of epigenetic mechanisms and their clinical applications.

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

CARDIOVASCULAR PATHOLOGY, published by Elsevier Science Inc, is a distinguished journal dedicated to the dissemination of high-quality research in the fields of cardiology, pathology, and cardiovascular medicine. With an ISSN of 1054-8807 and an E-ISSN of 1879-1336, this journal has established itself as a vital resource for researchers, clinicians, and students alike. It is positioned in the Q2 quartile for both cardiology and pathology, indicating its significant impact and relevance in these disciplines. The journal offers a platform for innovative studies, reviews, and clinical insights, aiming to enhance our understanding of cardiovascular conditions and their pathological underpinnings. With an H-index that showcases its scholarly influence, CARDIOVASCULAR PATHOLOGY is committed to advancing the field through rigorous peer review and open dialogue among professionals. The journal is accessible through institutional subscriptions, making it an essential reference point for ongoing research through its convergence of knowledge from 1992 through 2024.

BIOMARKERS is a distinguished journal published by Taylor & Francis Ltd, focusing on the critical intersection of biochemistry, clinical biochemistry, and health-related toxicology. With a robust history of publication since 1996 and ongoing contributions through to 2024, the journal serves as a vital platform for researchers, professionals, and students keen on exploring innovative biomarker research that spans various domains within the life sciences. The journal is currently ranked in the Q3 quartile in key areas such as Biochemistry and Health, demonstrating its reputation in the scientific community. Although it operates under a subscription model, BIOMARKERS remains an essential resource for advancing knowledge on biomarkers in health and disease, reflecting the latest advancements and methodologies within the rapidly evolving landscape of biomedical research. Researchers looking to publish in this influential journal can expect a rigorous peer-review process aimed at ensuring the dissemination of high-quality scientific inquiry.

Drug and Chemical Toxicology is a well-respected journal in the fields of toxicology, pharmacology, and public health, published by Taylor & Francis Ltd. Since its inception in 1978, this journal has diligently explored the effects and mechanisms of chemical exposures on health and the environment, fulfilling a crucial role in advancing scientific understanding and safeguarding public health. The journal is indexed across prestigious databases and features an impressive array of articles categorized within the Q2 and Q3 quartiles across various categories in 2023, reflecting its significance in Chemical Health and Safety as well as Environmental and Occupational Health disciplines. With an extensive reach and a focus on interdisciplinary research, Drug and Chemical Toxicology offers a rich repository of original research, reviews, and methodological advancements, catering to a diverse audience of researchers, professionals, and students dedicated to the betterment of safety and health standards. Although not an open-access publication, its articles are widely accessible to the academic community, ensuring that critical innovations and insights are shared for the greater good.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.